Biogen (BIIB) is a biotechnology company in the Health Care sector. Listed on the NASDAQ, Biogen is a component of the S&P 500 index. As of 2026-06-10, the stock is trading at $194.24.
Key Metrics & Risk
Based on 5-year historical data from Yahoo Finance (daily returns, annualized using 252 trading days).
| Metric | Value |
|---|---|
| Latest Price | $194.24 |
| Latest Date | 2026-06-10 |
| Expected Return (Annualized) | -8.79% |
| Risk / Std Dev (Annualized) | 34.29% |
| Sharpe Ratio (rf=4.5%) | -0.39 |
S&P 500 Context
- Sector: Health Care
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Index: S&P 500 Component
Risk/Return Profile
The stock shows an annualized expected return of -8.79% with an annualized volatility of 34.29%. The Sharpe ratio of -0.39 (assuming 4.5% risk-free rate) indicates negative risk-adjusted returns relative to the risk-free rate.
Modern Portfolio Theory Positioning
This stock is plotted on the S&P 500 Modern Portfolio Theory chart which visualizes the risk/return trade-off across all S&P 500 components. The chart uses Sharpe ratio as the color dimension, allowing quick identification of stocks with superior risk-adjusted performance.
Fundamentals
| Metric | Value |
|---|---|
| Market Cap | 28.68B |
| Enterprise Value | 30.96B |
| Trailing P/E | 20.89 |
| Forward P/E | 11.67 |
| Price to Book | 1.54 |
| Price to Sales | 2.89 |
| EV/Revenue | 3.12 |
| EV/EBITDA | 8.75 |
| Profitability | | | Profit Margin | 13.8% | | Operating Margin | 22.9% | | ROE | 7.7% | | ROA | 5.95% |
| Growth | | | Revenue Growth | 1.9% | | Earnings Growth | 31.1% |
| Financial Health | | | Total Revenue | 9.94B | | Total Debt | 6.56B | | Total Cash | 4.28B | | Free Cash Flow | 1.93B | | Operating Cash Flow | 2.59B |
| Price & Technical | | | 52W High | $205.97$ | | 52W Low | $121.05$ | | 50-Day Avg | $188.0$ | | 200-Day Avg | $172.55$ | | Beta | 0.18 | | Shares Outstanding | 0.15B | | Float Shares | 0.15B | | Insider Holdings | 0.17% | | Institutional Holdings | 96.58% | | Short Ratio | 4.01 | | Short % of Float | 3.6% |
| Analyst Targets | | | Target High | $300.0$ | | Target Low | $150.0$ | | Target Mean | $220.63$ | | Target Median | $217.5$ | | # of Analysts | 30 | | Recommendation | buy |
Disclaimer
This analysis is for educational purposes only and does not constitute financial advice. Past performance is not indicative of future results. Always conduct your own research or consult a qualified financial advisor before making investment decisions.